LeafCann is set to begin construction on an AU$50 million cultivation and processing center.
In late November, the FDA issued 15 warning letters to CBD companies and published a fact sheet detailing their safety concerns for CBD products. The FDA says they cannot deem CBD to be generally recognized as safe and that they will not tolerate making unsubstantiated health claims, marketing to children, using CBD as an ingredient in foods and marketing it as a dietary supplement.
How are hemp and CBD regulated? How does the FDA treat CBD as a drug or as a food ingredient? Nathan Libbey takes a stab at those questions and more in this piece.
Using copyright law, a cannabis business can utilize an arsenal of tools to defend its brand against counterfeiting.
You don’t want to miss this complimentary virtual program on January 15th.
What are the rules about cannabis-infused cosmetics in the EU and will there be any clarity any time soon?
The cannabis edibles industry is still immature and it will take time to bring all the necessary risk mitigation processes into place, but one excellent place to start is to seriously consider standardizing concentrates to a THC marker.
A full year after cannabis is approved for Schedule II prescription dispensation, the NHS gets on board – but reluctantly and in one of the most restrictive programs in Europe.
The International Association of Cannabinoid Medicines held a three-day conference on the efficacy of the drug with calls for more activism, formal trials and patient access.
An Italian Minister explained their decision in a parliamentary inquiry, citing noncompliance with EU GMP standards
